Immunology & Finance
AbbVie beats estimates as new drugs offset Humira decline
By Intent.Health Team • April 29, 2026
What’s happening
AbbVie reported stronger-than-expected results, driven by newer immunology drugs like Skyrizi and Rinvoq replacing lost revenue from Humira.
What’s changing / Business impact
-
Transition away from blockbuster dependency.
-
Growth now driven by: newer therapies.
-
Signals successful portfolio diversification.
Why this matters
Pharma companies often face revenue drops after patent expirations.
This shows:
-
Growth depends on: pipeline strength and replacement strategy.
-
Companies that fail to transition face sharp declines.
-
Innovation cycles directly impact financial stability.